Aligos Therapeutics General and Administrative Expenses 2011-2026 | ALGS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Aligos Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
30.6 M	26.4 M	28.5 M	17.9 M	10 M	3.2 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
30.6 M	3.2 M	19.5 M

Quarterly General and Administrative Expenses Aligos Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.16 M	5.56 M	5.05 M	-	4.63 M	6.38 M	6.67 M	-	6.44 M	9.25 M	8.51 M	-	5.26 M	7.58 M	6.45 M	-	6.47 M	6.56 M	5.78 M	-	4.22 M	4.1 M	3.42 M	-	2.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
9.25 M	2.78 M	5.8 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	54 M	$ 2.19	-9.77 %	$ 226 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Cabaletta Bio CABA	19.2 M	$ 3.34	0.45 %	$ 3.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Codexis CDXS	55.1 M	$ 1.02	1.49 %	$ 74.9 M	USA
AbCellera Biologics ABCL	83.2 M	$ 3.74	3.6 %	$ 1.12 B	Canada
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Cerus Corporation CERS	75.9 M	$ 2.6	1.37 %	$ 480 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	37.9 M	$ 3.87	-0.39 %	$ 116 M	France
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
CNS Pharmaceuticals CNSP	5.61 M	$ 3.23	2.22 %	$ 1.23 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	67.6 M	$ 41.75	0.19 %	$ 1.32 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	449 M	$ 36.14	1.23 %	$ 3.75 B	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Amarin Corporation plc AMRN	200 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Aileron Therapeutics ALRN	13.9 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Catalyst Pharmaceuticals CPRX	63.1 M	$ 23.77	2.99 %	$ 2.91 B	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Corbus Pharmaceuticals Holdings CRBP	13.9 M	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	14.2 M	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	16.8 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	35.8 M	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Champions Oncology CSBR	9.34 M	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Citius Pharmaceuticals CTXR	18.2 M	$ 0.72	-2.34 %	$ 4.84 M	USA
Athira Pharma ATHA	26.1 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	21 M	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	8.19 M	$ 3.88	-8.92 %	$ 247 M	USA